Donepezil,a drug for Alzheimer’s disease,promotes oligodendrocyte generation and remyelination
文献类型：期刊论文
| 作者 | Xue Cui4; Yue Guo3; Jiahui Fang4; Changjie Shi4; Na Suo3; Ru Zhang4; Xin Xie4 |
| 刊名 | 中国药理学报:英文版
 |
| 出版日期 | 2019 |
| 卷号 | 40.0期号:011页码:1386 |
| 关键词 | donepezil aricept oligodendrocyte oligodendrocyte progenitor cell differentiation myelin sheaths remyelination CNS demyelinating disorders multiple sclerosis |
| ISSN号 | 1671-4083 |
| 英文摘要 | Myelin sheaths play important roles in neuronal functions.In the central nervous system(CNS),the myelin is formed by oligodendrocytes(OLs),which are differentiated from oligodendrocyte precursor cells(OPCs).In CNS demyelinating disorders such as multiple sclerosis(MS),the myelin sheaths are damaged and the remyelination process is hindered.Small molecule drugs that promote OPC to OL differentiation and remyelination may provide a new way to treat these demyelinating diseases.Here we report that donepezil,an acetylcholinesterase inhibitor(AChEI)developed for the treatment of Alzheimer's disease(AD);significantly promotes OPC to OL differentiation.Interestingly,other AChEls,including huperzine A,rivastigmine,and tacrine,have no such effect indicating that donepezil's effect in promoting OPC differentiation is not dependent on the inhibition of AChE.Donepezil also facilitates the formation of myelin sheaths in OPC-DRG neuron co-culture.More interestingly,donepezil also promotes the repair of the myelin sheaths in vivo and provides significant therapeutic effect in a cuprizone-mediated demyelination animal model.Donepezil is a drug that has been used to treat AD safely for many years;our findings suggest that it might be repurposed to treat CNS demyelinating diseases such as MS by promoting OPC to OL differentiation and remyelination. |
| 资助项目 | [Ministry of Science and Technology of China] ; [Chinese Academy of Sciences] ; [National Natural Science Foundation of China] |
| 语种 | 英语 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/294944]  |
| 专题 | 中国科学院上海药物研究所 |
| 作者单位 | 1.Stake Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences 2.中国科学院大学 3.CAS Key Laboratory of Receptor Research,the National Center for Drug Screening,Shanghai Institute of Materia Medica,Chinese Academy of Sciences 4.Shanghai Key Laboratory of Signaling and Disease Research,Laboratory of Receptor-based Bio-medicine,School of Life Sciences and Technology,Tongji University |
| 推荐引用方式 GB/T 7714 | Xue Cui,Yue Guo,Jiahui Fang,et al. Donepezil,a drug for Alzheimer’s disease,promotes oligodendrocyte generation and remyelination[J]. 中国药理学报:英文版,2019,40.0(011):1386. |
| APA | Xue Cui.,Yue Guo.,Jiahui Fang.,Changjie Shi.,Na Suo.,...&Xin Xie.(2019).Donepezil,a drug for Alzheimer’s disease,promotes oligodendrocyte generation and remyelination.中国药理学报:英文版,40.0(011),1386. |
| MLA | Xue Cui,et al."Donepezil,a drug for Alzheimer’s disease,promotes oligodendrocyte generation and remyelination".中国药理学报:英文版 40.0.011(2019):1386. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。